Cargando…
Comorbidities in interstitial lung diseases
Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal refl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488735/ https://www.ncbi.nlm.nih.gov/pubmed/28049126 http://dx.doi.org/10.1183/16000617.0027-2016 |
_version_ | 1784792724852965376 |
---|---|
author | Margaritopoulos, George A. Antoniou, Katerina M. Wells, Athol U. |
author_facet | Margaritopoulos, George A. Antoniou, Katerina M. Wells, Athol U. |
author_sort | Margaritopoulos, George A. |
collection | PubMed |
description | Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair quality of life, impact upon the respiratory status of the patients, and ultimately lead to disease progression and death. Therefore, early identification and accurate treatment of comorbidities is essential. |
format | Online Article Text |
id | pubmed-9488735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-94887352022-11-14 Comorbidities in interstitial lung diseases Margaritopoulos, George A. Antoniou, Katerina M. Wells, Athol U. Eur Respir Rev Reviews Fibrosing lung disorders include a large number of diseases with diverse behaviour. Patients can die because of the progression of their illness, remain stable or even improve after appropriate treatment has been instituted. Comorbidities, such as acute and chronic infection, gastro-oesophageal reflux, pulmonary hypertension, lung cancer, cardiovascular diseases, and obstructive sleep apnoea, can pre-exist or develop at any time during the course of the disease and, if unidentified and untreated, may impair quality of life, impact upon the respiratory status of the patients, and ultimately lead to disease progression and death. Therefore, early identification and accurate treatment of comorbidities is essential. European Respiratory Society 2017-01-03 /pmc/articles/PMC9488735/ /pubmed/28049126 http://dx.doi.org/10.1183/16000617.0027-2016 Text en Copyright ©ERS 2017. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
spellingShingle | Reviews Margaritopoulos, George A. Antoniou, Katerina M. Wells, Athol U. Comorbidities in interstitial lung diseases |
title | Comorbidities in interstitial lung diseases |
title_full | Comorbidities in interstitial lung diseases |
title_fullStr | Comorbidities in interstitial lung diseases |
title_full_unstemmed | Comorbidities in interstitial lung diseases |
title_short | Comorbidities in interstitial lung diseases |
title_sort | comorbidities in interstitial lung diseases |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488735/ https://www.ncbi.nlm.nih.gov/pubmed/28049126 http://dx.doi.org/10.1183/16000617.0027-2016 |
work_keys_str_mv | AT margaritopoulosgeorgea comorbiditiesininterstitiallungdiseases AT antonioukaterinam comorbiditiesininterstitiallungdiseases AT wellsatholu comorbiditiesininterstitiallungdiseases |